Truist Financial Corp Reduces Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Truist Financial Corp lessened its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 226,637 shares of the medical equipment provider’s stock after selling 24,354 shares during the quarter. Truist Financial Corp owned approximately 0.06% of Intuitive Surgical worth $76,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. Portside Wealth Group LLC boosted its stake in shares of Intuitive Surgical by 8.2% during the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Intuitive Surgical by 58.0% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after acquiring an additional 3,054 shares during the last quarter. Kades & Cheifetz LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at $230,000. Blair William & Co. IL raised its position in shares of Intuitive Surgical by 3.1% during the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after purchasing an additional 11,400 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in shares of Intuitive Surgical by 21.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after purchasing an additional 129,194 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In other news, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the transaction, the vice president now directly owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the sale, the vice president now directly owns 110 shares in the company, valued at approximately $43,677.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the sale, the vice president now owns 26,877 shares in the company, valued at $10,349,795.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 249,418 shares of company stock valued at $96,300,959. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Trading Up 0.6 %

Intuitive Surgical stock traded up $2.21 during midday trading on Friday, hitting $375.33. 927,845 shares of the stock were exchanged, compared to its average volume of 1,564,565. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The stock has a market capitalization of $133.13 billion, a price-to-earnings ratio of 67.75, a PEG ratio of 4.82 and a beta of 1.36. The stock’s 50-day simple moving average is $386.19 and its 200 day simple moving average is $345.95.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter last year, the firm posted $1.00 earnings per share. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. Equities analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ISRG shares. Robert W. Baird reduced their price target on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a report on Friday, April 19th. Barclays lifted their price target on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Jefferies Financial Group lifted their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Stifel Nicolaus lifted their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. Finally, StockNews.com cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.